$27.18
-0.39 (-1.41%)
Open$27.52
Previous Close$27.57
Day High$27.95
Day Low$26.32
52W High$34.39
52W Low$6.21
Volume—
Avg Volume2.36M
Market Cap4.41B
P/E Ratio—
EPS$-0.83
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+3.9% upside
Current
$27.18
$27.18
Target
$28.24
$28.24
$22.54
$28.24 avg
$42.65
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 87.08M | 64.08M | 421.41M |
| Net Income | -141,821,396 | -93,928,365 | -114,600,480 |
| Profit Margin | -162.9% | -154.7% | -27.2% |
| EBITDA | -152,166,932 | -106,379,119 | -127,773,532 |
| Free Cash Flow | — | — | -89,915,808 |
| Rev Growth | +35.9% | +35.9% | +7.1% |
| Debt/Equity | — | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |